CONTEXT: Much of pediatric drug use is off-label because appropriate pediatric studies have not been conducted and the drugs have not been labeled by the US Food and Drug Administration (FDA) for use in children. In 1997, Congress authorized the FDA to grant extensions of marketing rights known as "pediatric exclusivity" if FDA-requested pediatric trials were conducted. As a result, there have been over 100 product labeling changes. The publication status of studies completed for pediatric exclusivity has not been evaluated. OBJECTIVE: To quantify the dissemination of results of studies conducted for pediatric exclusivity into the peer-review literature. DESIGN: Cohort study of all trials conducted for pediatric exclusivity between 1998 and 2004 as determined by MEDLINE and EMBASE searches through 2005, the subsequent labeling changes, and the publication of those studies in peer-reviewed journals. We categorized any labeling changes resulting from the studies as positive or negative for the drug under study. We then evaluated aspects of the studies and product label changes that were associated with subsequent publication in peer-reviewed medical journals. MAIN OUTCOME MEASURES: Publication of the trial data in peer-reviewed journals. RESULTS: Between 1998 and 2004, 253 studies were submitted to the FDA for pediatric exclusivity: 125 (50%) evaluated efficacy, 51 (20%) were multi-dose pharmacokinetic, 34 (13%) were single-dose pharmacokinetic, and 43 (17%) were safety studies. Labeling changes were positive for 127/253 (50%) of studies; only 113/253 (45%) were published. Efficacy studies and those with a positive labeling change were more likely to be published. CONCLUSIONS: The pediatric exclusivity program has been successful in encouraging drug studies in children. However, the dissemination of these results in the peer-reviewed literature is limited. Mechanisms to more widely disperse this information through publication warrant further evaluation.
CONTEXT: Much of pediatric drug use is off-label because appropriate pediatric studies have not been conducted and the drugs have not been labeled by the US Food and Drug Administration (FDA) for use in children. In 1997, Congress authorized the FDA to grant extensions of marketing rights known as "pediatric exclusivity" if FDA-requested pediatric trials were conducted. As a result, there have been over 100 product labeling changes. The publication status of studies completed for pediatric exclusivity has not been evaluated. OBJECTIVE: To quantify the dissemination of results of studies conducted for pediatric exclusivity into the peer-review literature. DESIGN: Cohort study of all trials conducted for pediatric exclusivity between 1998 and 2004 as determined by MEDLINE and EMBASE searches through 2005, the subsequent labeling changes, and the publication of those studies in peer-reviewed journals. We categorized any labeling changes resulting from the studies as positive or negative for the drug under study. We then evaluated aspects of the studies and product label changes that were associated with subsequent publication in peer-reviewed medical journals. MAIN OUTCOME MEASURES: Publication of the trial data in peer-reviewed journals. RESULTS: Between 1998 and 2004, 253 studies were submitted to the FDA for pediatric exclusivity: 125 (50%) evaluated efficacy, 51 (20%) were multi-dose pharmacokinetic, 34 (13%) were single-dose pharmacokinetic, and 43 (17%) were safety studies. Labeling changes were positive for 127/253 (50%) of studies; only 113/253 (45%) were published. Efficacy studies and those with a positive labeling change were more likely to be published. CONCLUSIONS: The pediatric exclusivity program has been successful in encouraging drug studies in children. However, the dissemination of these results in the peer-reviewed literature is limited. Mechanisms to more widely disperse this information through publication warrant further evaluation.
Authors: R L Findling; S H Preskorn; R N Marcus; R D Magnus; F D'Amico; P Marathe; M D Reed Journal: J Am Acad Child Adolesc Psychiatry Date: 2000-08 Impact factor: 8.829
Authors: Earl Silverman; Lynn Spiegel; David Hawkins; Ross Petty; Donald Goldsmith; Laura Schanberg; Ciaran Duffy; Paul Howard; Vibeke Strand Journal: Arthritis Rheum Date: 2005-02
Authors: D A Geller; S L Hoog; J H Heiligenstein; R K Ricardi; R Tamura; S Kluszynski; J G Jacobson Journal: J Am Acad Child Adolesc Psychiatry Date: 2001-07 Impact factor: 8.829
Authors: K Wade Foster; Sheila Fallon Friedlander; Helene Panzer; Mahmoud A Ghannoum; Boni E Elewski Journal: J Am Acad Dermatol Date: 2005-11 Impact factor: 11.527
Authors: Earl Silverman; Richard Mouy; Lynn Spiegel; Lawrence K Jung; Rotraud K Saurenmann; Pekka Lahdenne; Gerd Horneff; Immaculada Calvo; Ilona S Szer; Karen Simpson; John A Stewart; Vibeke Strand Journal: N Engl J Med Date: 2005-04-21 Impact factor: 91.245
Authors: P Winner; A D Rothner; J Saper; R Nett; M Asgharnejad; A Laurenza; R Austin; M Peykamian Journal: Pediatrics Date: 2000-11 Impact factor: 7.124
Authors: Jennifer S Li; Eric L Eisenstein; Henry G Grabowski; Elizabeth D Reid; Barry Mangum; Kevin A Schulman; John V Goldsmith; M Dianne Murphy; Robert M Califf; Daniel K Benjamin Journal: JAMA Date: 2007-02-07 Impact factor: 56.272
Authors: P Brian Smith; Jennifer S Li; M Dianne Murphy; Robert M Califf; Daniel K Benjamin Journal: Hypertension Date: 2008-02-19 Impact factor: 10.190